|Day's Range||25,253.97 - 25,382.37|
|52 Week Range||22,887.12 - 26,951.81|
Stocks opened lower after wavering in early trading, suggesting that U.S. equities may not yet be in the clear following last week’s selloff. The S&P 500 (^GSPC) fell 0.25%, or 6.82 points, and the Nasdaq (^IXIC) slipped 0.52%, or 39.05 points, as of 9:35 a.m. ET. The S&P 500 and Dow each fell more than 4% for the week, while the Nasdaq’s weekly losses came in around 3.7%.
U.S. stocks are mixed Monday as technology companies continue to slump and the Commerce Department said retail sales remained sluggish in September. The S&P 500 and other major U.S. indexes are coming ...
Sears' controlling shareholder, Edward Lampert, stepped down as CEO but will remain chairman. Click here to register for a free online video in which TheStreet's retirement expert Robert Powell and an all-star panel run down all you need to know. Wall Street Overview Stocks declined on Monday, Oct. 15, amid escalating tensions between the U.S. and Saudi Arabia over the death of a prominent Saudi journalist in Turkey last month as well as renewed concerns for trade disputes between the U.S. and its major economic partners.
Investors are digesting earnings reports and a disappointing retail sales report following a rout that saw stocks drop more than 4% last week.
U.S. stock benchmarks fell at the start of trade on Monday, resuming a retreat for the major benchmarks that resulted in the worst weekly losses since March. The decline for stocks come after an iconic retailer announced that it was filing from protection from creditors and as banks rolled out third-quarter results. The Dow Jones Industrial Average slipped by 52 points, or 0.2%, at 25,289, the S&P 500 index declined by about 0.2% at 2,758. Meanwhile, the Nasdaq Composite Index fell about 0.7% to 7,443. In corporate news, Bank of America Corp. reported third-quarter results that beat expectations ahead of the market's official open. Separately, retailer Sears Holdings Corp. filed for bankruptcy as had been widely expected. Last week's decline in stocks were partly fueled by a surge in government bond yields, which can translate to higher borrowing costs for corporations and individuals.
U.S. stocks dropped at open on Monday as rising tensions between Western powers and Saudi Arabia added to worries over rising borrowing costs and the impact of tariffs following the three indexes' biggest ...
Global stocks weaken as geopolitical and trade tensions keep investors cautious following last week's selling on Wall Street. Saudi Arabia has vowed to react to any punishment meted out following the disappearance of prominent journalist Jamal Khashoggi in Turkey last week. U.S. stocks set for more red at the open, with the Dow indicated 20 points lower at the bell after better-than-expected third quarter earnings from Bank of America.
STOCKSTOWATCHTODAY BLOG Not Too Bad. The Dow Jones Industrial Average was heading lower Monday morning, following a nerve-racking week, but the damage isn’t too great…yet. Trade with China is still an issue, and fears about higher oil prices have been added to the mix due to tensions between the U.
Alnylam Pharmaceuticals Inc. shares dropped 1.8% in Monday premarket trade after the company announced that it intends to apply for full U.S. approval of its rare disease drug, rather than a faster-than-usual approval, signifying a more extended approval timeline for the therapy. The drug, givosiran, is currently in a phase 3 clinical trial, with preliminary results expected in early 2019. Alnylam plans to submit a "rolling" new drug application with the Food and Drug Administration starting this year, with full clinical trial results from the phase 3 trial to be submitted in mid-2019. Givosiran is intended for acute hepatic porphyria, a group of rare genetic diseases characterized by attacks that can be life-threatening, as well as chronic and painful symptoms. Alnylam's decision to go for full approval is "not a surprise to us: this plan is, in our opinion, a byproduct of faster than expected enrollment of the phase III Envision trial, and we'd be buying the stock on any weakness that ensues," said Stifel analyst Paul Matteis, who noted that company management had previously suggested that this might happen. Alnylam shares have dropped 23.8% over the last three months, compared with a 1.2% decline in the S&P 500 and a 1.3% rise in the Dow Jones Industrial Average .